FundaMental Pharma launches with EUR 10 million in Seed financing led by BGV and Thuja Capital to advance a First-in-Class neuroprotectant
Retrieved on:
Thursday, November 17, 2022
Growth, Dementia, Science, Chemistry, Partnership, Medtech, Physician, Patient, Neurodegeneration, Fundamental, Thuja, Heidelberg University, Drug development, Amyotrophic lateral sclerosis, Federal Ministry of Budget and National Planning (Nigeria), BGV, ALS, Amyotrophy, Health, Economy, EUR, Investment, Pharmaceutical industry, Renewable energy
FundaMental scientists have discovered an entirely new class of drugs that safely counteract glutamate excitotoxicity, a common cause of neurodegeneration.
Key Points:
- FundaMental scientists have discovered an entirely new class of drugs that safely counteract glutamate excitotoxicity, a common cause of neurodegeneration.
- For more information, please visit: www.fundamentalpharma.com
BioGeneration Ventures (BGV) is a venture capital company, with a focus on early-stage European biotech companies. - BGV applies its expertise in a rigorous process to select the most compelling opportunities with the best prospects for exit.
- Thuja Capital Management (Thuja Capital) manages several venture capital funds aimed at building and scaling companies in the fields of (bio)pharmaceuticals, medtech and digital health.